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1. Introduction
Small  vessels  refer  to  arterioles,  capillaries  and  venules.  According  to  an  international
consensus  conference,  small  vessel  vasculitides  include,  ANCA-associated  vasculitis
(granulomatosis with polyangitis [Wegener’s],  Churg-Strauss syndrome, microscopic pol‐
yangiitis),  cryoglobulinaemic  vasculitis,  Henoch-Scholein  purpura,  and cutaneous  leuko‐
cytoclastic angiitis [1].
2. ANCA-associated vasculitis
2.1. Cryoglobulinaemic vasculitis
Cryoglobulinaemia refers to circulating cryoglobulins. Cryoglobulins are immunoglobulins,
which precipitate in temperatures below 37oC and dissolve upon rewarming [2]. Cryoglobu‐
linaemia is classified in 3 types based on clonality and immunoglobulin class. In particular,
type I consists of monoclonal IgM or IgG immunoglobulin, type II is a mixture of monoclo‐
nal IgM and polyclonal IgG, while type III is a mixture of polyclonal IgM and IgG. Type II
and III are also called “mixed”, since both contain a mixture of IgM and IgG immunoglobu‐
lins [3]. The IgM component of type II cryoglobulins has rheumatoid factor activity (can
bind to the Fc portion of IgG). All 3 types of cryoglobulinaemia may or may not result from
an underlying disorder. In the absence of an identifiable cause cryoglobulinaemia is charac‐
terized as “essential”.
Circulating cryoglobulins induce damage through 2 mechanisms: type I monoclonal IgM
cryoglobulins, due to the large size of IgM and their high concentration levels – usually as‐
© 2013 Katsiari et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
sociated with Waldenström disease– result in hyperviscosity-induced vascular damage. On
the other hand, type II and III mixed cryoglobulins in combination with complement com‐
ponents form immune complexes, which deposit in capillaries and small arterioles leading
to vascular inflammation [3]. Patients with symptomatic mixed cryoglobulinaemic vasculitis
typically display low serum levels of complement C4, reflecting complement consumption
via the classical, immune complexed-mediated activation pathway. Palpable purpura repre‐
sents a typical clinical manifestation. Skin biopsy reveals small vessel leukocytoclastic vas‐
culitis namely inflammation and destruction of the vessel wall along with
polymorphonuclear leukocyte nuclear debris. Involvement of internal organs, most com‐
monly peripheral nerves, kidneys and joints will dictate prognosis and treatment decisions.
Clinical and laboratory features of cryoglobulinaemia are summarized in Table1.
Treatment of mixed cryoglobulinaemic syndrome depends essentially on two parameters:
First the type and severity of manifestations and second the underlying disease. It is appa‐
rent that the identification and treatment of the underlying cause is of paramount impor‐
tance. Mixed cryoglobulinaemic syndrome is typically divided as hepatitis virus C (HCV) –
related or not.
CRYOGLOBULINAEMIA
TYPE I
monoclonal
IgM or IgG
TYPE II
monoclonal IgM + polyclonal IgG
TYPE III
polyclonal IgM
+ polyclonal IgG
Essential Secondary Essential Secondary Essential Secondary
Waldenström
Myeloma
Lymphoma
HCV
Myeloma
Lymphoma
Autoimmune
diseases
Autoimmune diseases
Chronic Inflammatory
diseases
HYPER – VISCOSITY
Raynaud’s
Digital ischemia
Hyperviscosity syndrome
CRYOGLOBULINAEMIC VASCULITIS
Purpura, Arthritis, Raynaud’s,
Renal disease, Neuropathy
CLINICAL SYNDROME
Table 1. Clinical and laboratory characteristics of cryoglobulinaemia.
2.2. Treatment of HCV related cryoglobulinaemic vasculitis
2.2.1. Aiming the virus: Treatment of chronic HCV
The majority of cases with cryoglobulinaemia are considered to be induced by HCV. Evi‐
dence of HCV infection is usually displayed by serum antibodies against the virus or pres‐
ence of HCV-RNA. It should be noted however that false negative results do occur. If
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suspicion of HCV infection is strong further examination of the cryoprecipitate, where both
antibodies and RNA are concentrated, should be performed. Management of patients in this
category should take place in collaboration with a hepatologist
The role of  interferon alpha (INFα) in the treatment of  cryoglobulinaemic vasculitis  has
been examined approximately 2 decades ago. In an early study, among 53 patients with
HCV –  related cryoglobulinaemic  vasculitis,  only  patients  who displayed a  drop in  the
virus RNA levels showed clinical improvement.  Reduction of RNA levels was restricted
to patients who received INFα in addition to conventional treatment [4]. Moreover, vire‐
mia, cryoglobulinaemia and clinical symptoms returned following INFα cessation. Apart
from INFα therapeutic  potential,  this  as  well  as  similar  studies  showed that  clinical  re‐
sponse parallels the levels of viremia.
Addition of the broad spectrum anti-viral agent rivabirin proved to add therapeutic benefit
to INFα monotherapy [5, 6]. More recently, PEGylated INFα combined with ribavirin was
shown to have superior efficacy compared to non-pegylated INFα / ribavirin combination
[7-9]. PEGylation is a process where polyethylene molecules (PEG) are covalently attached
to, in this case, INFα producing a molecule with prolonged pharmacokinetics. A recent up‐
date of recommendations by the American Association for the Study of Liver Diseases is
shown in Table 2 [10].
INFα
(SC per week) plus
Ribavirin
(orally per day)
180 μg PEG-INFα-2a + BW<75kg: 1000mg,BW"/>75kg: 1200mg
or
1 – 5 μg PEG-INFα-2b +
BW<65kg: 800mg,
BW=65-85kg: 1000mg,
BW=85-105kg: 1200mg BW"/>105kg: 1400mg
SC: subcutaneous, PEG-INFα: PEGylated interferon alpha, BW: body weight
Table 2. Antiviral combination treatment in HCV-related cryoglobulinaemic vasculitis
There are no definite guidelines regarding duration of treatment. Treatment of HCV infec‐
tion is recommended to last from 24 weeks (for virus genotypes 2 and 3) to 48 weeks (geno‐
types 1 and 4). The rational behind this recommendation lies on the observation that if viral
response has not been achieved within this time frame, it is highly unlikely that prolonga‐
tion of treatment will lead to substantial and sustained viral response [10]. However, in the
case of cryoglobulinaemic vasculitis accompanying HCV infection, a less strict approach is
endorsed, where besides viral levels, clinical and immunologic features are also taken into
account [7, 11]. Prolongation of antiviral therapies may be appropriate in a subset of patients
who display clinical benefit and no drug intolerance [3].
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2.2.2. Downregulation of cryoglobulins: Rituximab
Although many patients achieve virological response using INFα and ribavirin, several con‐
siderations still exist: only 50% patients carrying genotype 1, which is the most common
genotype in Europe and Americas, respond. Also, pegylated form of INFα as well as ribavir‐
in are contraindicated in patients with compromised renal function, which may prove puz‐
zling when treating patients with severe renal involvement.
Rituximab is an anti-CD20 chimeric monoclonal antibody, which results in prompt deple‐
tion of circulating and tissue B cells. Cryoglobulins are produced by B cells. Hence, B-cell
depleting biological therapy using Rituximab, holds theoretical promise of down-regulating
the production and circulating levels of cryoglobulins. Following few cohort studies with
promising results [12-16], a prospective randomized controlled trial to examine the role of
rituximab in the treatment of patients non-responding to antiviral therapy has only recently
been presented [17]. Twenty-four non-responders were included and followed for 12
months. Twelve patients were managed according to conventional strategies (maintain or
increase immunosuppression) and twelve received rituximab (as administered in vasculitis:
375mg/m2 every week for 4 weeks). Following 6 months, 10 patients (83%) receiving rituxi‐
mab achieved remission compared to 1 patient (8%) in the control group. At this point it ap‐
pears that rituximab could be used in patients who did not respond to conventional
treatment. In addition there is no restriction regarding renal function. However, the risk of
serious infection remains an important consideration. Of note, in patients with high concen‐
trations of IgM-k cryoglobulins with rheumatoid factor activity, complex formation with rit‐
uximab can occur resulting in severe systemic reactions.
A significant proportion of patients treated with conventional therapy despite sustained vi‐
rological response relapsed during long-term follow-up, posing a significant question re‐
garding the role of HCV on the pathophysiology of the disease [18]. Off label experience
with rituximab to date may provide relevant insight: in patients receiving rituximab, relap‐
ses did not parallel virus load but coincided with the recovery of peripheral B cells. It has
been proposed that B cell proliferation and thus subsequent cryoglobulin production can be‐
come independent of HCV overtime [3].
2.2.3. Vasculitis treatment: Plasmapheresis and conventional immunosuppression
Severe, life-threatening disease. Plasmapheresis is reserved for patients with acute, serious,
life-threatening disease such as progressive renal failure, severe neuropathy, intestinal ische‐
mia, alveolar hemorrhage and digital necrosis [19]. Removing cryoglobulins from the circu‐
lation presumably hinders immune-complex mediated vasculopathy leading to prompt
improvement. However, following termination of plasma exchange a rebound overproduc‐
tion of cryoglobulins may occur. Therefore, concomitant treatment aiming to mute cryoglo‐
bulin production is required. High dose glucocorticoids in conjunction with
cyclophosphamide (CyP) represent the standard therapeutic regimen. Following the para‐
digm of ANCA-associated vasculitis, azathioprine and mycophenolate mofetil (MMF) are
often used for remission maintenance or in the place of CyP when the disease is less severe
(doses are presented in Table 2) [20]. Duration and efficacy of such treatment modalities
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have not been assessed in controlled clinical trials. Consequently, therapeutic decisions are
usually taken on an individual basis according to clinical response, personal history, comor‐
bidity as well as the centre’s experience to treat such patients.
Antiviral treatment is usually avoided until acute flare has been controlled [21, 22]. Exac‐
erbation of the underlying vasculitis due to INFα and restrictions regarding ribavirin ad‐
ministration  in  patients  with  impaired  renal  function  remain  the  main  considerations.
The same may apply to rituximab where monotherapy rather than combination with an‐
tiviral therapy is recommended by some authorities during the treatment of a severe dis‐
ease  [23].  Following  remission  of  severe  inflammatory  phenomena,  antiviral  treatment
should be administered.
Mild-to-moderate disease. Manifestations, such as purpura, arthralgias/arthritis, mild pro‐
teinuria/hematuria with normal serum creatinine or peripheral sensory neuropathy repre‐
sent mild-to-moderate disease activity. In cases of HCV-related disease, viral clearance with
combination therapy as described above is the initial treatment of choice.
Low-dose corticosteroids (<7.5–10 mg/day) can be administered for more efficient control of
symptoms (arthritis/arthralgias, persisting purpura, etc.). Sequential or simultaneous ad‐
ministration [16, 24] of corticosteroids with IFNα did not influence the sustained virological
response in treated patients. Nevertheless, whenever possible it is prudent to avoid cortico‐
steroids during the initial course of antiviral therapy. Quick tapering of corticosteroids is al‐
so advised since long-term administration does not seem to grant a favorable effect on
vasculitis, while can harm the liver function.
The use of immunosuppression in cyoglobulinaemic vasculitis is summarized in Table 3.
Drug Dosage Comments
Prednisolone 60 mg/day for 1 month tapered to 15mg/day at 3 months
IV methylprednisolone 500-1,000 mg/day
for 3 successive days in critical organ
manifestations
Cyclophosphamide
(CyP) for 3-6 pulses Oral CyP (2 mg/Kg/day) can be used
Rituximab IV 375 mg/m2/week for 4 pulses In intolerance to CyP and in young patientswith severe disease
Azathioprin 2 mg /kg/ day
Mycophenolate Mofetil 2 g/day In patients with moderate renal involvementwho cannot take CyP
Plasmapheresis three times weekly for two to threeweeks In critical organ manifestations
Table 3. Immunosuppressive treatment for cryoglobulinaemic vasculitis
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2.3. Treatment of non-HCV mixed cryoglobulaenimic syndrome
According to current EULAR recommendations, patients presenting with mixed cryoglobu‐
linaemic syndrome non-related to HCV or other disorder should be treated as patients with
ANCA – associated vasculitis [8].
Although rare, cases associated to hepatitis B virus (HBV) have been documented. Antiviral
therapy with lamivudine or entecavir has led to remission in isolated case reports. Myelo‐
proliferative diseases and most commonly B cell lymphoma may also be the cause of mixed
cryoglobulinaemia. Prompt diagnosis and appropriate treatments should be applied.
Among autoimmune diseases, Sjogren’s syndrome and systemic lupus erythematosus most
commonly are associated with cryoglobulinaemia.
2.4. Special considerations
Patients with end Stage Renal Disease. Patients are treated with hemodialysis or peritoneal
dialysis. Survival is comparable with with that of end stage renal diseases. Kidney trans‐
plantation can be performed. High rate of relapse has been recorded (up to 70%). However,
recurrent disease does not lead to graft loss and thus relapse risk does not forbid transplan‐
tation in patients with end stage renal disease. Another concern in cases of HCV-related dis‐
ease is that robust immunosuppression following transplantation may exacerbate HCV
infection. Fortunately, this has proven to be the exception rather than the rule [25].
Cancer Risk. B-cell lymphoma has been reported in up to 25% of patients with mixed cryo‐
globulinaemic syndrome. Patients are usually diagnosed within 10 years. Low levels of
gamma globulins may predate neoplastic transformation. Standard chemotherapy in combi‐
nation with rituximab is usually required. HCV infection increases the B-cell lymphoma risk
by 20-30% and is associated with increased frequency of liver cancer, which is diagnosed in
up to 10% of patients [26].
2.5. Prognosis
Prognosis mainly depends on whether vital organ(s) are involved.
Most studies have examined glomerulonephritis (GN) where 10-year survival rate was re‐
ported to be 30-50%. However, therapeutic progress substantially improved prognosis since
10-year survival has recently been raised to almost 80%. Male gender, HCV infection, high
cryocrit, low C3 and raised serum creatinine at baseline are considered bad prognostic fac‐
tors. Intestinal ischaemia and alveolar haemorrhage have high mortality rates (>80%). In pa‐
tients with HCV infection, carriers of genotype 2 and 3 along with early virological response
have the best outcome. Of interest, changes of cryocrit level do not seem to correlate with
clinical activity. It would be interesting, however, to examine whether the degree of solubili‐
ty at 37°C or a decline in the temperature at which the cryoproteins precipitate might better
correlate with response to treatment [27].
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3. Henoch-Schonlein Purpura
Henoch-Schönlein purpura (HSP) is the most common vasculitis syndrome of childhood, al‐
though is also well described in adults. Clinical features include palpable non-thrombocyto‐
penic purpura, particularly over the buttocks and lower extremities, arthritis (or arthralgia)
affecting primarily large joints, diffuse abdominal pain and renal involvement with micro‐
scopic or gross haematuria, and/or proteinuria. There are also reports on the involvement of
other organs, including lungs, brain and testes. Generally, it is a benign disorder that fol‐
lows an intercurrent illness, usually an upper respiratory tract infection.
HSP is an immune complex-mediated small vessel vasculitis. Serologic studies document
elevated levels of IgA and activation of the alternate pathway of the complement system.
The characteristic histopathologic finding of HSP is leukocytoclastic vasculitis with IgA de‐
posits with affected vessels.
Although prognosis is excellent in children with HSP, a small minority of patients develop
long-term complications, and primarily renal disease. In adults, the risk of significant renal
disease is increased. Management of HSP includes supportive care to ameliorate acute
symptoms, as well as targeted treatment to decrease the risk of complications (usually due
to gastrointestinal complications) and to prevent chronic renal insufficiency. Targeted treat‐
ment is summarized in Table 4.
3.1. Supportive management
Treatment of HSP is primarily supportive and includes adequate hydration and sympto‐
matic relief  of pain.  Edema of the lower extremities and buttocks is improved with bed
rest  and/or elevating the affected area.  Acetaminophen and non-steroidal anti-inflamma‐
tory  drugs  (NSAIDs)  help  with  mild  rash  and  arthritis.  However,  NSAIDs  should  be
used cautiously in elderly persons due to increased risk of renal impairment and gastro‐
intestinal bleeding.
3.2. Targeted treatment
3.2.1. Glucocorticosteroids
Oral steroids. Oral steroids are used in patients with painful cutaneous edema, severe rash,
scrotal and testicular involvement, renal involvement and abdominal pain [28]. There is
some supportive evidence for the use of corticosteroids in severe abdominal pain. In a sys‐
temic review that included three randomized trials and 12 retrospective studies, predniso‐
lone at a dose of 1 mg/Kg/day for two weeks or 2 mg/Kg/day for one week may decrease the
intensity and duration of abdominal pain and may decrease the frequency of bowel intus‐
susceptions and thus surgical interventions [29-31] .
Renal involvement is a common finding in HSP. Although the prognosis of HSP is excellent
in children, persistent renal disease can cause long-term morbidity. This risk of significant
renal disease is greater in adults with HSP [32]
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However, it is not clear if corticosteroids decrease the likelihood of renal disease
[29;30;32-39]. A meta-analysis suggested that early use of corticosteroids reduced the odds
of developing persistent renal disease [29]. However, concerns are raised over the validity of
this analysis, which included studies with different treatment protocols and follow-up time
[36]. A more recent meta-analysis of four randomized controlled trials showed no significant
difference in the risk of persistent renal disease at 6 and 12 months in children treated with
prednisone for 2-4 weeks after initial presentation compared with placebo or supportive
treatment [34]. Thus there are no convincing data to support the routine use of oral steroids
as a measure to prevent renal disease in patients with uncomplicated HSP.
High dose steroids. Steroid treatment with high intravenous doses (pulses) and/or long
term oral administration are the treatment of choice in acute HSP glomerulonephritis in chil‐
dren [32]. Methylprednisolone pulse therapy was evaluated in a prospective study with 38
children with severe HSP nephritis, defined as nephrotic syndrome at presentation and/or
50% or more crescentic glomeruli on biopsy [37]. Clinical recovery was achieved in 20 chil‐
dren. Renal biopsy in these children showed a significant decrease of the activity index with
a decrease or disappearance of IgA deposits.
Steroids can be used alone or in combination with immunosuppressive agents (i.e., cyclo‐
sporin A, cyclophosphamide, mycophenolate mofetil, and azathioprine) [32].
3.2.2. Cyclophosphamide
Cyclophosphamide (CyP) is widely used in the treatment for the majority of vasculitides. In
HSP, CyP has been used mainly for rapidly progressive glomerulonephritis (GN), while
case reports of successful management of pulmonary hemorrhage also exist [33].
In a randomized controlled trial, 56 children with severe HSP nephritis were treated with
oral cyclophosphamide (90mg/m2/day) without steroids for 42 days. At final follow-up,
48.2% of children had full recovery, 39.3% had persistent abnormalities and 12.5% ended up
with end-stage renal failure or death. No patient with crescents in 50% or more of glomeruli
went on to full recovery. The authors concluded that CyP had no significant efficacy [39].
The combination of CyP with steroids has provided better outcome. In a retrospective study,
high dose corticosteroids plus oral CyP (2mg/kg/day for 12 weeks) significantly reduced
proteinuria in children with HSP GN [35]. Oral prednisolone (1.5 mg/kg/day) combined
with an 8-week course of CyP (2 mg/kg/day) in 9 children with severe HSP nephritis, result‐
ed in remission of proteinuria in 7 children [38]. Triple therapy with oral CyP (2.5mg/kg/
day), methylprednizolone (30 mg/kg/day [maximum 1g/day], for 3 days), and intravenous
urokinase (5000 U/kg/day [max 180.000], for 7 days) reduced protein excretion and mesan‐
gial IgA deposition compared with the group that received the same therapeutic combina‐
tion without CyP [40]. In another study, combined therapy with intravenous pulse
methylprednisolone (for 3 days), oral CyP (for 2 months), oral dipyridamole (for 6 months)
and oral prednisolone (for 3 months) resulted in normalization of glomerular filtration rate
in all but 1 patient [41]. Combined therapy with prednisolone, CyP, heparin/warfarin, and
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dipyridamole, in 14 children with severe HSP nephritis, followed for 7.5 years, resulted in a
significant improvement of histological grade of nephritis [42].
In adults, adding CyP to steroids provided no benefit in a 12-month, open-label trial of 54
patients with severe HSP GN [43].
3.2.3. Cyclosporin A
Cyclosporin A (CsA) is an effective immunosuppressive agent used for different immune-
mediated glomerular diseases [32].
In a randomized study of of 24 children with nephrotic-range proteinuria or crescenting
HSP nephritis, CsA was more efficacious compared to IV pulses of methylprednisolone [44].
In two retrospective studies by the same group, CsA plus steroids was found to be beneficial
in HSP children with nephrotic syndrome [45,46]. In a retrospective study of 29 children
with nephrotic-range proteinuria treated with CsA plus steroids, 23 achieved stable remis‐
sion, while 6 patients became CsA-dependent [47]. In a clinical trial with a mean follow-up
of 6 years all patients responded to CsA therapy (plus ACE inhibitors), however some pa‐
tients developed CsA- dependent nephritis [48].
CsA plus steroids,  either as initial  treatment or after other immunosuppressive drugs in
a small case series of 5 adult patients with HSP with nephrotic-range proteinuria showed
beneficial effects on proteinuria and preservation of renal function, after a follow-up pe‐
riod of 5 years [49].
Overall, despite the data reporting proteinuria reduction by CsA in patients with HSP neph‐
ritis, this treatment is not supported by RCTs and cautiousness should be exercised for po‐
tential nephrotoxicity of CsA.
3.2.4. Azathioprine
Azathioprine is used in combination with steroids mostly in children with crescent HSP
nephritis [32].
Azathioprine plus steroids showed beneficial effects in a clinical trial of 21 children with
severe  HSP  GN.  Treatment  with  either  oral  or  intravenous  (IV)  corticosteroids  led  to
comparable  outcome [50].  Retrospective  studies  also  support  the  use  of  combination  of
azathioprine with steroids for the treatment of severe HSP nephritis in children [51]. Ear‐
ly treatment with azathioprine plus steroids prevented progression of chronic kidney dis‐
ease  [52].  The  combination  was  effective  in  improving  histopathological  changes  [53];
however, 2 of the 10 patients treated with azathioprine showed definite tubulointerstitial
nephritis at followup biopsy [54].
3.2.5. Mycophenolate mofetil
Mycophenolate mofetil (MMF) appears to be a promising therapeutic agent in many auto‐
immune diseases such as lupus nephritis, vasculitis and in IgA nephropathy.
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There is limited evidence to support the use of MMF in HSP. Case reports [55-57] suggest a
beneficial effect of MMF on HSP with complications. In six children in whom steroid thera‐
py has failed, MMF was able to control complications and to sustain disease remission.
MMF was well tolerated [58]. More recently, MMF along with ACE inhibitors reduced pro‐
tein excretion and improved renal function in 12 children with HSP and nephrotic range
proteinuria, who failed steroid treatment (20-25mg/kg/day) [59].
3.2.6. Rituximab
The efficacy of rituximab (RTX) in chronic HSP has been suggested by a case report. Three
pediatric patients were treated with RTX for severe refractory chronic Henoch-Schönlein
purpura, characterized mainly by neurologic and gastroenterological symptoms resistant to
steroids and CyP. All 3 patients responded to 1 or 2 courses of RTX without serious adverse
events [60]. In another case report one patient with moderate nephritis and severe skin HSP
responded to RTX [61].
3.2.7. Plasma exchange
The addition of plasma exchange to common immunosuppressives and steroids have shown
efficacy in patients with HSP and severe of extra-renal manifestations (alveolar and cerebral
hemorrhage, haemorrhagic pancolitis, extensive vasculitic leg ulcers) [62-64]. Plasma ex‐
change has also been used as sole treatment in patients with severe HSP nephritis with en‐
couraging results [65,66].
3.2.8. Intravenous immunoglobulin
The clinical use of intravenous immunoglobulin (IVIg) has been extended beyond antibody-
deficiency syndromes, to a wide variety of clinical conditions, such as neuroimmunological
diseases, and systemic autoimmune diseases. Kawasaki disease was the first primary vascu‐
litis in which IVIg had become the standard treatment of care. IVIg has also shown benefi‐
cial effects in patients with ANCA-associated vasculitis (AAV) refractory to standard
therapy with prednisone and CyP [67]. In HSP, IVIg inhibited disease progression in isolat‐
ed case reports [68,69].
3.3. Additional treatments
From a pathophysiological point of view, the removal of any source of chronic bacterial
challenge, which may trigger HSP episodes, should theoretically be beneficial [70]. This is
the reason why there are reports about tonsillectomy and periodontal therapy in children
with HSP [71-73]. However, the therapeutic contribution of such approaches are difficult to
evaluate since are commonly used in combination with other therapies.
Antithrombotic  prophylaxis  with  warfarin,  dipyridamole,  and  acetylsalicylic  acid  has
been used along with immunosuppressive agents by several authors [70]. ACE inhibitors
have been shown to be efficacious in reducing proteinuria and should be added at  any
level of proteinuria.
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3.4. Emergencies
Patients with HSP may present with severe abdominal pain, gastrointestinal (GI) bleeding
and renal insufficiency. Up to 50% of patients with HSP and GI manifestations have occult
bleeding, but major hemorrhage occurs in only 5% and intussusceptions in 2% [74]. Other
manifestations may include bowel infract, perforation and pancreatitis, which may require
urgent surgical consultation.
Medication Indication Comments
Acetaminophen,
NSAIDs
Arthritis,
rash (mild)
Precautions: renal insufficiency and GI
bleeding (for NSAIDs)
Oral steroids painful cutaneous edema, severe rash,
scrotal and testicular involvement, renal
involvement and abdominal symptoms
Steroids may shorten the duration of
abdominal pain and the risk of surgical
interventions
In few RCTs, short-course of oral
prednisone does not prevent persistent
renal disease
IV pulse steroids Nephrotic range proteinuria, nephritic
syndrome
IV pulse steroids plus
Immunosuppression
Rapidly progressive glomerulonephritis,
pulmonary hemorrhage
CyP : no supporting RCT; serious side
effects
Azathioprine: no RCTs, cases of
tubulointerstitial nephritis
CsA: no RCTs, potential nephrotoxicity
MMF: limited data
Rituximab: limited data
Plasma exchange Refractory HSP nephritis
pulmonary and gastrointestinal
hemorrhage, cerebral hemorrhage
ACE inhibitors Proteinuria
Table 4. Medications used in the treatment of HSP
4. Idiopatic cutaneous vasculitis
Cutaneous vasculitis is a vasculitis confined to the dermis and is not a single disease. In
fact,  only  less  than  30% of  cutaneous  vasculitis  can  be  defined  as  idiopathic.  All  other
cases  are  systemic  vasculitides,  vasculitis  associated with  other  rheumatic  diseases  (sys‐
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temic  lupus  erythematosus,  rheumatoid  arthritis),  or  vasculitis  induced  by  malignancy,
infection  or  medication/toxin.  Therefore,  one  should  search  carefully  for  extracutaneous
manifestations of vasculitis and obtain a detailed medical history. Also mimics of vascu‐
litis,  such as antiphospolipid syndrome, should be ruled out.  Even idiopathic cutaneous
vasculitis is not a single entity. An international consensus conference defined cutaneous
leukocytoclastic  angiitis  as  isolated  cutaneous  leukocytoclastic  angiitis  without  systemic
vasculitis or glomerulonephritis [1]. This definition is controversial, since it requires biop‐
sy for diagnosis and even biopsy is not diagnostic. Other terms used under the umbrella
of idiopathic cutaneous vasculitis include hypersensitivity vasculitis, and urticarial vascu‐
litis [75]. There are few points to consider in diagnosing cutaneous leukocytoclastic angii‐
tis  (CLA).  First,  CLA  manifests  with  palpable  purpura.  On  biopsy,  cutaneous
leukocytoclastic angiitis is characterized by leukocytoclastic vasculitis in upper to middle
dermis (where small  vessles are located),  whereas necrotizing vasculitis in lower dermis
and  subcutaneous  fat  involves  medium-sized  vessels  associated  with  cutaneous  polyar‐
teritis  nodosa  and  other  systemic  vasculitides.  Serum  ANCA  tests  by  immunofluores‐
cence,  with  ELISA  for  MPO  and  PR3  to  exclude  ANCA-associated  vasculitis,  serum
cryoglobulin  test,  to  exclude  cryoglobulinaemic  vasculitis,  and  immunofluorescence  for
IgA deposits on skin biopsy, to exclude Henoch-Schonlein purpura, are necessary labora‐
tory tests in diagnosing cutaneous leukocytoclastic angiitis.
Treatment  of  idiopathic  cutaneous vasculitis  depends on the severity  of  lesions and the
extent  of  cutaneous involvement.  For example,  purpura is  a  manifestation of  superficial
dermal  small  vessel  vasculitis  with  no  serious  consequences.  Therefore  any  treatment
should be with few if any side effects. However, it should be reminded that what initial‐
ly appears to be isolated cutaneous vasculitis may be the presenting feature of an under‐
lying disease,  such as lymphoma or systemic vasculitis.  Therefore,  vigilance is  required.
Nodulal  lesions  and ulcers  are  caused by  medium-sized vessels  and suggest  cutaneous
polyarteritis  nodosa  or  other  systemic  vasculitides  Therefore,  more  intense  treatment  is
required.  It  should  be  mentioned  that  there  are  no  randomized  controlled  trials  and
treatment of idiopathic cutaneous vasculitis is based on case reports or small case series.
When cutaneous vasculitis is associated with a systemic disease one should treat the sys‐
temic  disease.  Also,  any  inciting  agent,  either  drug  or  infective  agent,  should  be  re‐
moved.  For  instance,  any  infectious  trigger  should  be  treated  with  antibiotics.  If  food
allergen is suspected, allergy testing is recommended, and if  positive,  elimination of the
relevant  food  is  tried,  since  low-antigen  diet  prevents  recurrences  of  palpable  purpura
[76]. Drugs that are used with variable efficacy in idiopathic cutaneous vasculitis include
non-steroidal anti-inflammatory drugs (NSAIDs), antihistamines (such as doxepin, lorata‐
dine,  and cetirizine),  colchicine,  hydroxychloroquine (HCQ),  dapsone,  and prednisolone.
However,  no  drug  is  universally  efficacious.  Colchicine  inhibits  neutrophil  chemotaxis.
Dapsone inhibits the alternative pathway of complement, and suppresses neutrophil che‐
motaxis. Hydroxychloroquine inhibits lysosomal enzyme release. The idiopathic leukocy‐
toclastic  cutaneous  small  vessel  vasculitis  is  often  self-limited  and  does  not  require
specific treatment.  Leg elevation,  avoidance of excessive standing, and administration of
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NSAIDs or antihistamines usually relieve symptoms, such as pruritus and burning sensa‐
tion. For persistent disease, colchicine is considered a drug of first choice [77]. Colchicine
is effective in 50% of patients with cutaneous leukocytoclastic vasculitis within 2 weeks,
although  in  a  randomized  controlled  trial  colchicine  (0.5  mg  twice  daily)  for  a  month
was  no  more  efficacious  than  topical  emollients  [78].  Patients  with  chronic  cutaneous
venulitis are usually resistant to treatment.  Dapsone (100-200 mg daily) may be very ef‐
fective  in  leukocytoclastic  vasculitis  and  urticarial  vasculitis.  Dapsone  appears  to  have
synergistic effects with colchicine or pentoxifylline [79]. HCQ is more often used in urti‐
carial  vasculitis  associated  with  connective  tissue  diseases.  Prednisolone,  at  the  initial
dose of 0.5-1 mg/Kg/day for 2 weeks with rapid tapering, can be very effective in acute
severe episodes. However, Idiopathic Cutaneous Small Vessel Vasculitis can be active for
10 years and prednisolone monotherapy is not recommended for chronic use. In difficult
to treat cases, azathioprine may be used with low-dose prednisolone. Other medications
that have been used include CsA (2.5-5 mg/kg/day, in two doses).
4.1. Urticarial vasculitis
Urticarial vasculitis(UV) is characterized by persistent (greater than 24 hours) urticarial skin
lesions and leukocytoclastic vasculitis on histology. It is associated with low serum comple‐
ment (hypocomplementaemic urticarial vasculitis, HUV) or normal serum complement lev‐
els (normocomplementaemic urticarial vasculitis, NUV). HUV is usually a systemic disease
and associated with systemic lupus erythematosus (SLE) with autoantibodies against C1q.
NUV is usually confined to the skin and rarely associated with SLE. Nearly 50% of patients
with idiopathic UV have autoantibodies against IgE or IgE receptor.
Treatment of UV is based on manifestations. For mild skin lesions antihistamines, colchi‐
cines, dapsone, HCQ and prednisolone are used. The addition of reserpine (0.3-0.4 mg/day)
to antihistamines may improve UV symptoms [80]. For extracutaneous disease or chronic
necrotizing skin lesions prednisolone is used, often in association with azathioprine, myco‐
phenolate mofetil (MMF), CsA, or CyP. IVIg and plasmapheresis have been used in difficult
to treat urticarial vasculitis [76]. Rituximab, a monoclonal antibody against CD20, present on
mature B cells, was successfully tried in a patient with UV with angioedema unresponsive
to prednisolone, CsA and plasmapheresis [8].
4.2. Cutaneous polyarteritis nodosa
In mild cases, colchicine or NSAIDs may suffice. In moderate to severe cases, prednisolone
is administered at an initial dose of 1 mg/kg/day, usually in conjunction with HCQ, dap‐
sone, methotrexate, azathioprine, CyP, or intravenous immunoglobulin [81]. Mizoribine, an
inhibitor of inosine monophosphate and guanosine monophosphate synthetase, which in‐
hibits T and B cell proliferation, is also efficacious. Warfarin or clopidogrel are helpful adju‐
vant treatment [82].
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5. Precautions
Certain precautions should be observed to reduce side effects of drugs used. CyP dose
should be adjusted for renal function and age.
Patients should be checked for tuberculosis with chest x-rays and PPD skin test, and patients
with latent tuberculosis should receive prophylaxis with isoniazid plus vitamin B6. Patients
on IV pulse CyP, receive antiemetic drug (ondaserton) immediately prior to and 8 hours af‐
ter the CyP pulse. On the day of IV CyP pulse, patients receive oral or IV hydration with 2-3
liters of fluid. They also receive IV 2-mercaptoethanesulfonate (mesna) (20% of CyP dose)
immediately before and at 2, 4 and 8 hours after the CyP pulse to reduce irritation of urinary
bladder. The dose of next IV CyP pulse is adjusted to keep nadir white blood cell (WBC)
count (12-14 days after the IV pulse) >3,000/µL. The rate of leucopenia, infections, and gona‐
dal toxicity is reduced in the IV pulse CyP compared to oral CyP regimen [83,84]. Oral mes‐
na is also beneficial for patients on oral CyP.
According to a recent study ever-tobacco smoking and previous episode of hemorrhagic
cystitis were strong predictors for the development of cancer in the urinary tract. Thus pa‐
tients with these characteristics need close surveillance with urine cytology tests.
All patients receiving CyP are advised to take prophylaxis against Pneumocystis jiroveci
with trimethoprime/sulphamethoxazole (800/160 mg thrice weekly).
Gonadal failure is a common side effect in patients treated with CyP, where the risk increas‐
es in parallel with the increase of the cumulative dose received. No standard care to pre‐
serve gonadal function has been proposed for patients with small vessel vasculitis under
CyP. For similar issues encountered in female patients with systemic lupus erythematosus
(SLE) two protocols exist: administration of leuprolide acetate with or without transdermal
estrogen and depo-progesterone for contraception. Leuprolide should be administered 10-14
days prior to each CyP infusion. In men with SLE, administration of intramuscular monthly
injections of testosterone has been proposed. Analogous approaches should probably be
adopted for young patients with small vessel vasculitis at risk.
Patients on immunosuppression should not be vaccinated with live attenuated vaccines.
They can and should be vaccinated with dead pathogens. Patients with granulomatosis with
polyangiitis(Wegener’s granulomatosis) exhibit adequate antibody [85] and cell-mediated
immune response to influenza vaccines [86].
INFα may cause hepatic dysfunction and extreme caution is advised in patients with cirrho‐
sis. PEG-INFα and ribavirin are contraindicated in renal impairment (creatinine clearance
[ClCr] <50ml). Ribavirin can cause haemolytic anaemia.
Colchicine can induce gastrointestinal upset (diarrhoea, vomiting) and rarely cytopenia.
Dapsone can cause granulopenia and severe haemolysis in patients with glucose-6-phos‐
phate dehydrogenase (G6PD) deficiency. Therefore, before initiation of dapsone, G6PD
should be measured, and then full blood count regularly. Side effects of HCQ are rare and
include retinopathy and cytopenias.
Updates in the Diagnosis and Treatment of Vasculitis230
6. Conclusion
Small vessel vasculitis may be a manifestation of systemic vasculitis or may be confined to
the skin. Therefore, biopsy of skin lesion with immunofluorescence and careful search for
systemic disease are mandatory for the correct diagnosis. The treatment of cryoglobulinae‐
mic vasculitis is based on the underlining aetiology. In HCV positive patients with severe
vasculitic manifestations, immunosuppressives with plasmapheresis is the modality of
choice. Anti-HCV treatment is administered after the control of inflammatory manifesta‐
tions. In HCV-associated cryoglobulinaemic vasculitis with mild disease, anti-HCV treat‐
ment may suffice. HSP is usually a self limited disease. In patients with HSP complications,
corticosteroids remain the main treatment. In severe refractory cases, plasmapheresis in con‐
junction with immunosuppressives have been tried. Idiopathic cutaneous leukocytoclastic
vasculitis is most of the time a mild disease and does not require toxic medications. Rituxi‐
mab is a promising new treatment for systemic or refractory small vessel vasculitis.
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